Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angel Biotechnology, a biopharmaceutical contract manufacturer has planned to establish a joint venture company (JVC) with Russian firm, Materia Medica.
Subscribe to our email newsletter
Following the deal, 51% of the JVC will be owned by Materia Medica and 49% by Angel Biotechnology.
The companies intend to commission new product programmes, manage production and increase the size of Angel’s GMP facility at Cramlington.
The facility will be managed, operated and staffed by Angel, supported by Angel’s infrastructure, and covered by Angel’s licences.
The JVC will also occupy a non-GMP development laboratory.